Cargando…

Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study

BACKGROUND: Cryopyrin-associated periodic syndrome (CAPS) is a rare disease. Knowledge on the quality of life (QoL) and the disease’s societal impact is limited. Canakinumab is used in increasing frequency for the treatment of CAPS. METHODS: Observational study in Dutch CAPS patients. Patients compl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulders-Manders, Catharina M., Kanters, Tim A., van Daele, Paul L. A., Hoppenreijs, Esther, Legger, G. Elizabeth, van Laar, Jan A. M., Simon, Anna, Hakkaart-van Roijen, Leona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910566/ https://www.ncbi.nlm.nih.gov/pubmed/29678136 http://dx.doi.org/10.1186/s13023-018-0799-1

Ejemplares similares

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age
por: Caorsi, Roberta, et al.
Publicado: (2013)

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
por: Walker, Ulrich A, et al.
Publicado: (2021)

Live‐attenuated vaccines in a cryopyrin‐associated periodic syndrome patient receiving canakinumab treatment during infancy
por: Watanabe, Misa, et al.
Publicado: (2017)

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
por: Brogan, Paul A., et al.
Publicado: (2019)

The genetic and clinical characteristics and effects of Canakinumab on cryopyrin-associated periodic syndrome: a large pediatric cohort study from China
por: Shu, Zhou, et al.
Publicado: (2023)

Orphan drugs expenditure in the Netherlands in the period 2006–2012
por: Kanters, Tim A, et al.
Publicado: (2014)

Association between societal costs and treatment response in children and adolescents with ADHD and their parents. A cross-sectional study in the Netherlands
por: van der Kolk, Annemarie, et al.
Publicado: (2015)

In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era
por: Brouwer, Werner, et al.
Publicado: (2021)

Update of the Dutch manual for costing studies in health care
por: Kanters, Tim A., et al.
Publicado: (2017)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome
por: Elmi, Abdulkadir A., et al.
Publicado: (2019)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
por: Hansmann, Sandra, et al.
Publicado: (2011)

Neurology of the Cryopyrin-Associated Periodic Feversyndrome
por: Parker, T, et al.
Publicado: (2015)

Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic
por: Huls, Samare P. I., et al.
Publicado: (2021)

National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
por: Bibalo, C, et al.
Publicado: (2011)

Assessing the impact of caregiving on informal caregivers of adults with a mental disorder in OECD countries: A systematic literature review of concepts and their respective questionnaires
por: Bremmers, Leonarda G. M., et al.
Publicado: (2022)

Multiplier Effects and Compensation Mechanisms for Inclusion in Health Economic Evaluation: A Systematic Review
por: Krol, Marieke, et al.
Publicado: (2023)

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
por: Gillespie, Justin, et al.
Publicado: (2010)

Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System
por: Keddie, Stephen, et al.
Publicado: (2018)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008)

Unified modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes
por: Gul, A, et al.
Publicado: (2015)

Burden of illness of hip fractures in elderly Dutch patients
por: Kanters, T. A., et al.
Publicado: (2020)

Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P)
por: Bouwmans, Clazien, et al.
Publicado: (2013)

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
por: Koné-Paut, Isabelle, et al.
Publicado: (2011)

Cryopyrin-Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response
por: Yu, Justin R., et al.
Publicado: (2010)

Erythema nodosum in an adolescent patient with cryopyrin‐associated periodic syndrome
por: Chan, Linda, et al.
Publicado: (2018)

Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS)
por: Mamoudjy, Nafissa, et al.
Publicado: (2017)

The First Case Series of Cryopyrin-Associated Periodic Syndrome in Korea
por: Han, Jong Hee, et al.
Publicado: (2019)

Most Important Factors in Diagnosing Cryopyrin-Associated Periodic Syndrome
por: Lee, Soyoung, et al.
Publicado: (2021)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2017)

Employment and the associated impact on quality of life in people diagnosed with schizophrenia
por: Bouwmans, Clazien, et al.
Publicado: (2015)

Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments
por: Łaszewska, Agata, et al.
Publicado: (2022)

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2011)

Effectiveness of step-down versus outpatient dialectical behaviour therapy for patients with severe levels of borderline personality disorder: a pragmatic randomized controlled trial
por: Sinnaeve, Roland, et al.
Publicado: (2018)

Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome
por: Dhimolea, Eugen
Publicado: (2011)

Unified Modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes
por: Bozkurt, Yasemin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qpdl3vqbd6480kepknp7uh580o